Previous close | 30.47 |
Open | 28.97 |
Bid | 0.00 x 4000 |
Ask | 0.00 x 4000 |
Day's range | 28.30 - 29.40 |
52-week range | 28.30 - 54.93 |
Volume | |
Avg. volume | 30,620,631 |
Market cap | 163.238B |
Beta (5Y monthly) | 0.56 |
PE ratio (TTM) | 15.80 |
EPS (TTM) | 1.83 |
Earnings date | 29 Jan 2024 - 02 Feb 2024 |
Forward dividend & yield | 1.64 (5.67%) |
Ex-dividend date | 09 Nov 2023 |
1y target est | 40.10 |
Sign up now to see all the the picks and follow the 'Beat the S&P 500' strategy for up to 60% off for a limited time only!
Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine Comirnaty and the treatment Paxlovid -- saw its shares drop about 40%. This includes Pfizer's newer programs and what they may deliver in the future, as well as the company's valuation today. Is Pfizer a buy right now -- or a stock to avoid?
One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). Here are two other issues driving me toward hitting the "sell" button on this pharma stock. Since Albert Bourla took over as CEO in 2019, Pfizer has been on a buying spree.